Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study경증에서 중등도의 COVID-19 환자에 대한 Tocilizumab, netakimab 및 baricitinib: 관찰 연구Observational Study Published on 2022-08-242022-09-12 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adults hospitalized anti-IL-6R antibody Anticoagulant Antiviral average Baricitinib benefit blockers Blood C-reactive protein (CRP Clinical outcome Combination comparable COVID-19 CRP level Dexamethasone discharged dose Efficiency group groups hospital hospitalized patient Hydroxychloroquine IL-17A immunosuppressive inflamed tissues Inflammation Inflammatory marker JAK1/JAK2 inhibitor lactate dehydrogenase LDH marker Mild-to-moderate mild-to-moderate disease Mortality neutrophil neutrophil count Neutrophil-to-lymphocyte ratio NEWS2 observation Observational cohort study Patient previous study remained safety profile SARS-CoV-2 severe COVID-19 significant decrease significant increase significantly significantly increased Standard-of-care therapeutic therapy Tocilizumab treated [DOI] 10.1371/journal.pone.0273340 PMC 바로가기 [Article Type] Observational Study
High Monocyte Count Associated with Human Cytomegalovirus Replication In Vivo and Glucocorticoid Therapy May Be a Hallmark of DiseaseArticle Published on 2022-08-242022-11-16 Journal: International Journal of Molecular Sciences [Category] 치료기술, [키워드] caused CD14 Characteristics clinical model/translational medicine clinical response Clinical symptoms CMV comparable correlated corticosteroid therapy count COVID-19 cytomegalovirus cytomegalovirus (CMV) kinetics decrease defined definitions of cytomegalovirus disease described Dexamethasone disease dose glucocorticoid growth hallmark healthy subjects homogeneous homogeneous sample of subjects logarithmic phase of infection Human Increased Infection Infectious disease innate immune innate immune response investigated leukopenia lymphopenia macrophages molecular monocyte monocytes characteristics and analysis monocytosis mononucleosis neutropenia observation onset of fever pathogen detection Patient prodrome Replication Sample Significant steroid subject syndrome tested the median viral infection Viral load viral replication Viremia virome virus virus replication [DOI] 10.3390/ijms23179595 PMC 바로가기
Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone덱사메타손을 투여한 2019 코로나바이러스 질환(COVID-19) 입원 환자에서 렘데시비르 시작의 최적 시기Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] 95% CI acute respiratory distress addition applied benefit Clinical improvement Cohort coronavirus disease COVID-19 Cox regression models cumulative Dexamethasone difference drug exposure group Follow-up group hazard ratio Hong Kong hospital Hospital stay Hospitalization Hospitalized HRs IgG antibody In-hospital death increased risk initiated Initiation Length of hospital stay lower risk Multiple outcome Patient patients with moderate positive Probability progression Remdesivir significantly shorter Survivors syndrome time time to clinical improvement. Treatment Weighting were given WHO [DOI] 10.1093/cid/ciab728 PMC 바로가기 [Article Type] Article
Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone Research Published on 2022-08-192022-10-05 Journal: International journal of obesity (2005) [Category] 임상, 치료법, [키워드] adjusted Admission age Analysis association BMI body mass index Clinical course Clinical outcome clinical outcomes Cohort cohort of patient cohorts Comorbidities conducted COVID-19 patient CRP level death defined Dexamethasone dose fixed hospital hospitalised hospitalised COVID-19 patient ICU admission inflammatory status introduced Lymphocyte count multivariable analyses multivariable logistic regression non-ICU obesity objective opposite overweight Oxygen requirement Patient patients treated patients with obesity percentage pharmacokinetic prevalent repeated Result retrospective cohort study standard treatment supplemental oxygen translate treated [DOI] 10.1038/s41366-022-01204-1 [Article Type] Research
Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after T H 2-biased immunizationT H 2 편향 예방 접종 후 COVID-19 햄스터의 백신 관련 향상된 호흡기 병리학Article Published on 2022-08-162022-09-11 Journal: Cell Reports [Category] 유전자 메커니즘, 진단, [키워드] ADE alum animals antibody Antibody-dependent enhancement caused cellular coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccines CP: Immunology CP: Microbiology cytokine cytokine driver cytokine drivers Cytokines Dexamethasone dexamethasone treatment dysregulation eosinophil evaluate hamster host gene identify IL-13 IL-4 IL-5 immune immune responses immunization immunology Immunopathogenesis induce Infection interleukin lead lung lymphoid cell lymphoid cells Macrophage macrophages measles virus mechanism mechanism of immunopathogenesis Microbiology mRNA mRNAs pathology PROTECT Protein Protein vaccines respiratory Respiratory disease respiratory infections reveal RNA sequencing scRNA-seq Single-cell RNA sequencing Spike protein T helper TH2 immune responses transcriptomic analysis Treatment up-regulating vaccination Vaccine vaccine safety vaccine-associated enhanced respiratory disease. VAERD virus [DOI] 10.1016/j.celrep.2022.111214 PMC 바로가기 [Article Type] Article
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular LymphomaArticle Published on 2022-08-152022-11-15 Journal: Internal medicine (Tokyo, Japan) [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] anti-spike protein IgG Bendamustine coronavirus COVID-19 COVID-19 symptom COVID-19 symptoms detect Dexamethasone discharged exacerbated follicular Follicular lymphoma Immunocompromised Immunocompromised patient Immunocompromised patients lymphoma obinutuzumab obinutuzumab and bendamustine observation Patient Prolonged Prolonged COVID-19 Remdesivir SARS-CoV-2 vaccination subsequent Symptom the disease the patient treated [DOI] 10.2169/internalmedicine.9136-21 PMC 바로가기
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients토실리주맙의 적시 투여는 입원한 COVID-19 환자의 결과를 개선합니다Clinical Trial Published on 2022-08-122022-09-12 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] 30-Day mortality 95% CI administration clinical trial Course COVID-19 death determine Dexamethasone disease Efficacy Endpoint enrolled hazard ratio Hospital stay hospitalized COVID-19 patient hospitalized patient ICU IMPROVE IQR Mechanical mechanical ventilation median median age Mortality outcome oxygen support Patient post-hoc analysis primary endpoint Randomized Secondary objective significance level supplemental oxygen Support the disease Tocilizumab treated Treatment Ventilation was performed with COVID-19 [DOI] 10.1371/journal.pone.0271807 PMC 바로가기 [Article Type] Clinical Trial
Should RECOVERY have used response adaptive randomisation? Evidence from a simulation studyRandomized Controlled Trial Published on 2022-08-062022-10-04 Journal: BMC Medical Research Methodology [Category] SARS, 임상, [키워드] adaptive adaptive randomisation Adaptive trial Arm ARMS Care Community coronavirus COVID-19 COVID-19 mortality COVID-19 therapy defined Dexamethasone effective error rate estimate exhibiting FIVE fixed form hospitalised Hydroxychloroquine induce Lopinavir-ritonavir lower mortality Measures mortality rate other diseases Patient patient death patient subgroup performed Platform trial question randomisation randomised controlled trial Randomised Evaluation receiving recovery RECOVERY trial reduced reducing reduction REMAP-CAP representing Respiratory Support Response-adaptive randomization Simulation standard care Statistical power tested Treatment Trial Two-arm [DOI] 10.1186/s12874-022-01691-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trialRandomized Controlled Trial Published on 2022-08-042022-10-04 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상, [키워드] 1:1 28-day mortality 95% CI age assigned Clinical improvement clinical status clinical trial Controlled trial coronavirus disease COVID-19 death demonstrated Dexamethasone discharged Effect Efficacy enrolled Evidence High dose High-dose high-dose group hospitalised hospitalised COVID-19 patient hospitalised patient low dose low-dose male moderate no significant difference Open-label outcome oxygen Oxygen therapy Patient performed Pneumonia Primary outcome randomisation randomised Randomly receive reduced secondary seven-point ordinal scale severe COVID-19 Time to recovery worsening [DOI] 10.1183/13993003.02518-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Treatment strategies of COVID-19: A rheumatology perspectiveCOVID-19의 치료 전략: 류마티스학적 관점Review Published on 2022-08-012022-09-12 Journal: European journal of internal medicine [Category] COVID19(2023년), SARS, 진단, 치료법, 치료제, [키워드] absence acute respiratory syndrome adaptive approved authority Colchicine Coronavirus-2 Corticosteroid COVID-19 Critical Critically ill patient Dexamethasone DMARDs effective host cell Immunity Inflammatory response inhibitors interleukin-6 janus Kinase inhibitor mAbs monoclonal antibody off-label Perspective plethora progression Proinflammatory cytokine Remdesivir Replication rheumatologist rheumatology SARS-CoV-2 SARS-CoV-2 mAbs. SARS-CoV-2 pneumonia therapeutic strategy Treatment viral entry [DOI] 10.1016/j.ejim.2022.05.014 PMC 바로가기 [Article Type] Review